SubsidieMeestersThe first in-class non-opioid drug for treating moderate, severe, and persistent pain with no addiction nor tolerance
Tafalgie Therapeutics aims to develop non-opioid analgesics using innovative polypeptides from TAFA4 to provide effective, non-addictive pain relief and prevent chronic pain.
Projectdetails
Introduction
Tafalgie Therapeutics is a biopharmaceutical research company developing a new scientific approach for next-generation treatments, based on a true breakthrough innovation derived from the mechanism of action of an endogenous protein modulating the pain signal.
Ambition
Our ambition is to become the reference player in the field of pain medication by:
- Designing and proposing new active pharmaceutical ingredients for non-opioid analgesics.
- Addressing the context marked by the opioid crisis.
- Developing first-in-class polypeptides derived from TAFA4 and its peptide derivatives.
Goals
We aim to develop and bring to patients:
- More effective treatments.
- Well-tolerated options.
- Non-addictive solutions.
- Long-term treatments for the relief of acute pain (mild, moderate, and severe).
- Preventative measures for chronic pain.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 17.388.832 |
Tijdlijn
| Startdatum | 1-3-2024 |
| Einddatum | 30-11-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- TAFALGIE THERAPEUTICSpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Clinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic painSea4Us aims to clinically validate its novel analgesic Sea4Pain for chronic pain treatment, facilitating rapid market entry and sustainable growth through licensing and reinvestment. | EIC Accelerator | € 2.499.035 | 2024 | Details |
PN6047 - a breakthrough treatment of neuropathic painPharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development. | EIC Accelerator | € 2.493.000 | 2024 | Details |
PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).ATXA Therapeutics aims to advance NTP42, a novel drug for pulmonary arterial hypertension, through Phase II trials and licensing to accelerate market entry and diversify its drug portfolio. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market. | EIC Accelerator | € 2.498.816 | 2024 | Details |
Clinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic pain
Sea4Us aims to clinically validate its novel analgesic Sea4Pain for chronic pain treatment, facilitating rapid market entry and sustainable growth through licensing and reinvestment.
PN6047 - a breakthrough treatment of neuropathic pain
PharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development.
PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).
ATXA Therapeutics aims to advance NTP42, a novel drug for pulmonary arterial hypertension, through Phase II trials and licensing to accelerate market entry and diversify its drug portfolio.
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)
The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Oral oxytocin for abdominal painThis project aims to develop gut-stable peptide analgesics for effective oral treatment of chronic abdominal pain, addressing a significant unmet medical need and reducing socio-economic burdens. | ERC Proof of... | € 150.000 | 2023 | Details |
Chronic PAIN eradiCAtion by taRgeting Schwann cEllsPAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization. | ERC Proof of... | € 150.000 | 2023 | Details |
Disruptive Therapies for the long-term relief of Osteoarthritis PainThe Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life. | ERC Consolid... | € 1.998.885 | 2023 | Details |
PERSONALIZED NON-INVASIVE NEUROMODULATION IN PAINPersoNINpain aims to personalize chronic pain treatment by using brain connectivity metrics to optimize non-invasive neuromodulation techniques like rTMS for individual patients. | ERC Consolid... | € 1.618.278 | 2023 | Details |
TraffikGene-Tx: Targeted Peptide Carriers for RNA DeliveryTraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs. | EIC Transition | € 2.498.963 | 2023 | Details |
Oral oxytocin for abdominal pain
This project aims to develop gut-stable peptide analgesics for effective oral treatment of chronic abdominal pain, addressing a significant unmet medical need and reducing socio-economic burdens.
Chronic PAIN eradiCAtion by taRgeting Schwann cElls
PAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization.
Disruptive Therapies for the long-term relief of Osteoarthritis Pain
The Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life.
PERSONALIZED NON-INVASIVE NEUROMODULATION IN PAIN
PersoNINpain aims to personalize chronic pain treatment by using brain connectivity metrics to optimize non-invasive neuromodulation techniques like rTMS for individual patients.
TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery
TraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs.